FrancophonIA/ELRC3.0 huggingface dataset:
English: Aldurazyme is used in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; α L iduronidase deficiency) to treat the non-neurological symptoms of the disease (symptoms that are not connected with the brain or nerves).
Slovenian: Zdravilo Aldurazyme se uporablja pri bolnikih s potrjeno diagnozo mukopolisaharidoze tipa I (MPS I; tj. pomanjkanjem α-L-iduronidaze), in sicer za zdravljenje nenevroloških simptomov bolezni (ki niso povezani z možgani ali živčnim sistemom).
English: Laronidase is used as ‘enzyme replacement therapy', which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I, improving the patient's quality of life.
Slovenian: Laronidaza se uporablja kot „terapija z nadomestnimi encimi“, kar pomeni, da nadomešča encim, ki manjka bolnikom z mukopolisaharidozo tipa I. S tem se nadzorujejo simptomi te bolezni in izboljša bolnikova kakovost življenja.
English: Aldurazyme has been compared with placebo (a dummy treatment) in 45 patients aged six years and over with a confirmed diagnosis of MPS I. The main measure of effectiveness was the forced vital capacity (FVC, a measure of how well the lungs are working) and the distance the patients could walk over six minutes.
Slovenian: Zdravilo Aldurazyme so primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 45 bolnikih, starejših od šest let, pri katerih je bila potrjena diagnoza MPS I. Glavno merilo učinkovitosti je bila forsirana vitalna kapaciteta (FVC, tj. merilo delovanja pljuč) in razdalja, ki so jo bolniki lahko prehodili v šestih minutah.
English: The most common side effects in patients over the age of five years (seen in more than 1 patient in 10) are headache, nausea (feeling sick), abdominal pain (stomach ache), rash, arthropathy (damage to the joints), arthralgia (joint pain), back pain, pain in the extremities (hands and feet), flushing, pyrexia (fever) and reactions at the site of the infusion.
Slovenian: Najpogostejši neželeni učinki pri bolnikih, starejših od pet let (opaženi pri več kot 1 bolniku od 10), so glavobol, navzeja (slabost), bolečine v trebuhu, izpuščaji, artropatija (poškodbe sklepov), artralgija (bolečine v sklepih), bolečine v hrbtu, bolečine v okončinah (dlaneh in stopalih), zardevanje, pireksija (povišana telesna temperatura) ter reakcije na mestu infuzije.
English: MPS I is a rare, inherited disease, in which the level of α L iduronidase enzyme activity is much lower than normal.
Slovenian: Mukopolisaharidoza tipa I je redka dedna bolezen, pri kateri je stopnja delovanja encima α-L-iduronidaze mnogo nižja od normalne.
English: For the full list of all side effects reported with Aldurazyme, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Aldurazyme, glejte navodilo za uporabo.
English: The active substance in Aldurazyme, laronidase, is a copy of the human enzyme α L iduronidase.
Slovenian: Zdravilna učinkovina zdravila Aldurazyme, laronidaza, je kopija človeškega encima α-L-iduronidaza.
English: The CHMP decided that Aldurazyme gives effective control of the symptoms of MPS I. The Committee decided that Aldurazyme's benefits are greater than its risks and recommended that Aldurazyme be given marketing authorisation.
Slovenian: CHMP je zaključil, da zdravilo Aldurazyme zagotavlja učinkovit nadzor simptomov mukopolisaharidoze tipa I. Zaključil je, da so koristi zdravila Aldurazyme večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: The non-neurological symptoms of MPS I can be an enlarged liver, stiff joints that make moving more difficult, reduced lung volume, heart disease and eye disease.
Slovenian: Nenevrološki znaki mukopolisaharidoze tipa I so lahko povečanje jeter, togost sklepov, ki otežuje gibanje, manjši volumen pljuč, srčne bolezni in očesna obolenja.
English: Aldurazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS I or other inherited metabolic diseases.
Slovenian: Zdravljenje z zdravilom Aldurazyme mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z mukopolisaharidozo tipa I ali drugimi dednimi presnovnimi boleznimi.
English: Why has Aldurazyme been approved?
Slovenian: Zakaj je bilo zdravilo Aldurazyme odobreno?
English: In patients under five years of age, the most common side effects (seen in more than 1 patient in 10) are increased blood pressure, decreased oxygen saturation (a measure of how well the lungs are working), tachycardia (rapid heart rate), pyrexia and chills.
Slovenian: Pri bolnikih, mlajših od pet let, so najpogostejši neželeni učinki (opaženi pri več kot 1 bolniku od 10) zvišan krvni tlak, zmanjšana nasičenost s kisikom (merilo uspešnosti delovanja pljuč), tahikardija (hitro bitje srca), pireksija in mrzlica.
English: Aldurazyme is a solution for infusion (drip) into a vein that contains the active substance laronidase.
Slovenian: Zdravilo Aldurazyme je raztopina za infundiranje (kapalno infuzijo v veno), ki vsebuje zdravilno učinkovino laronidaza.
English: What is Aldurazyme used for?
Slovenian: Za kaj se zdravilo Aldurazyme uporablja?
English: How has Aldurazyme been studied?
Slovenian: Kako je bilo zdravilo Aldurazyme raziskano?
English: What is Aldurazyme?
Slovenian: Kaj je zdravilo Aldurazyme?
English: How does Aldurazyme work?
Slovenian: Kako zdravilo Aldurazyme deluje?
English: How is Aldurazyme used?
Slovenian: Kako se zdravilo Aldurazyme uporablja?
English: Content (concentration)
Slovenian: Vsebina (koncen tracija)
English: This summary was last updated in 12-2013.
Slovenian: Povzetek je bil nazadnje posodobljen 12-2013.
English: Skin reactions are seen in more than 80% of patients.
Slovenian: Kožne reakcije so bile opažene pri več kot 80 % bolnikov.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Erbitux on 29 June 2004.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Erbitux, veljavno po vsej Evropski uniji, izdala 29. junija 2004.
English: Erbitux is given once a week.
Slovenian: Zdravilo Erbitux se daje enkrat na teden.
English: The following infusions are 250 mg/m2 given over one hour.
Slovenian: Vsak naslednji odmerek je 250 mg/m2 in se infundira eno uro.
English: The full EPAR for Erbitux can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Erbitux je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Erbitux.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Erbitux.
English: The CHMP decided that Erbitux's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Erbitux večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Other information about Erbitux
Slovenian: Druge informacije o zdravilu Erbitux
English: Erbitux is given in the following ways:
Slovenian: Zdravilo Erbitux se uporablja na naslednje načine:
English: EPAR summary for the public cetuximab
Slovenian: Povzetek EPAR za javnost cetuksimab
English: • together with anticancer treatments containing irinotecan;
Slovenian: • skupaj z drugimi oblikami zdravljenja proti raku, ki vsebujejo irinotekan;
English: Between 79 and 89% of colorectal cancers and more than 90% of squamous cell cancers of the head and neck have EGFR on their cell surfaces.
Slovenian: Pri 79 do 89 % primerov raka kolona ali danke in več kot 90 % ploščatoceličnega raka glave in vratu je na površini tumorskih celic prisoten receptor za epidermalni rastni faktor.
English: For more information about treatment with Erbitux, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Erbitux preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: All of the studies looked at how long the patients lived without their cancer getting worse or how long they survived.
Slovenian: V vseh študijah so opazovali, kako dolgo se pri bolnikih bolezen ni poslabšala ali kako dolgo so živeli.
English: Patients must also be closely observed for any signs of allergic reaction for at least one hour after the end of the infusion.
Slovenian: Poleg tega jih je treba pozorno opazovati še najmanj eno uro po koncu infundiranja, ali se pojavijo znaki alergijske reakcije.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Erbitux.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The first infusion is given at a dose of 400 mg per square metre body surface area (calculated using the patient's height and weight) over two hours.
Slovenian: Odmerek pri prvem infundiranju znaša 400 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove mase in višine), ki ga bolniku infundiramo dve uri.
English: The most common side effects with Erbitux (seen in more than 1 patient in 10) are skin reactions such as rash, hypomagnesaemia (low blood magnesium levels), mild or moderate reactions linked to the infusion (such as fever, chills, dizziness and difficulty breathing), mucositis (inflammation of the lining of the mouth) and raised levels of some liver enzymes.
Slovenian: Najpogostejši neželeni učinki zdravila Erbitux (opaženi pri več kot 1 bolniku od 10) so kožne reakcije, kot so izpuščaji, hipomagneziemija (nizke ravni magnezija v krvi), blage do zmerne reakcije na infundiranje (kot so povišana telesna temperatura, mrzlica, omotica in oteženo dihanje), mukozitis (vnetje sluznice ustne votline) in povišane ravni nekaterih jetrnih encimov.
English: What benefit has Erbitux shown during the studies?
Slovenian: Kakšne koristi je zdravilo Erbitux izkazalo med študijami?
English: Erbitux should only be given under the supervision of a doctor who has experience in the use of anticancer medicines in a setting where facilities for resuscitation are available.
Slovenian: Zdravilo Erbitux se lahko jemlje le pod nadzorom zdravnika, ki ima izkušnje z uporabo zdravil za zdravljenje raka, in v ustanovi, v kateri je nemudoma na voljo oprema za oživljanje.
English: Erbitux can be associated with severe reactions during the infusion, so the patients must be monitored carefully while the medicine is being given.
Slovenian: Pri infundiranju zdravila Erbitux se lahko pojavijo hude reakcije, zato je treba bolnike med dajanjem zdravila skrbno nadzorovati.
English: In locally advanced cancer (when the tumour has grown but has not spread), Erbitux is given in combination with radiotherapy (treatment with radiation).
Slovenian: Pri lokalno napredovalem raku (kadar je tumor zrastel, vendar se ni razširil) se zdravilo Erbitux uporablja v kombinaciji z obsevanjem (radioterapijo).
English: Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain ‘wild-type' (non-mutated) versions of a family of genes called ‘RAS'.
Slovenian: Zdravilo Erbitux se uporablja pri bolnikih, katerih tumorske celice imajo na svoji površini beljakovino, imenovano receptor za epidermalni rastni faktor (EGFR), in vsebujejo „divje“ (nemutirane) oblike družine genov, imenovane „RAS“.
English: • three studies involved 2,199 patients whose disease had got worse while they were on previous treatment including irinotecan, oxaliplatin or both, or who could not receive these medicines.
Slovenian: • druge tri študije so vključevale 2 199 bolnikov, pri katerih se je bolezen poslabšala med predhodnim zdravljenjem, ki je vključevalo irinotekan ali oksaliplatin ali pa obe učinkovini, ali pri katerih teh zdravil ni bilo mogoče uporabiti.
English: Before receiving Erbitux, the patient must be given an antihistamine and a corticosteroid to prevent an allergic reaction.
Slovenian: Pred uporabo zdravila Erbitux je treba bolniku za preprečitev alergijskih reakcij dati antihistaminike in kortikosteroide.
English: For cancers of the head and neck, Erbitux was investigated in two main studies:
Slovenian: Pri raku glave in vratu so zdravilo Erbitux proučevali v dveh glavnih študijah:
English: These types of cancer affect the cells of the lining of the mouth or the throat, or of organs such as the larynx (voice box).
Slovenian: Ta vrsta raka prizadene celice sluznice ustne votline ali žrela oziroma organov, kot je grlo (govorni aparat).
English: • together with the oxaliplatin-containing treatment FOLFOX in patients who have not been treated before;
Slovenian: • skupaj s terapijo FOLFOX, ki vsebuje oksaliplatin, pri bolnikih, ki predhodno še niso bili zdravljeni;
English: • on its own when previous treatment containing oxaliplatin and irinotecan has failed and the patient cannot receive irinotecan.
Slovenian: • samostojno, kadar predhodno zdravljenje raka z zdravili, ki vsebujejo oksaliplatin in irinotekan, ni bilo uspešno in bolnik ne more več prejemati irinotekana.
English: For the full list of all side effects reported with Erbitux, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Erbitux, glejte navodilo za uporabo.
English: One of the studies also looked at the results separately in patients whose tumours carried wild-type forms of all RAS genes and patients with mutated forms of any RAS gene.
Slovenian: V eni študiji so ločeno analizirali tudi rezultate pri bolnikih, katerih tumorji so vsebovali divje tipe vseh genov RAS, in pri bolnikih z mutiranimi oblikami katerega koli gena RAS.
English: In the studies of cancer of the colon or rectum, Erbitux was shown overall to increase the time patients lived without their cancer getting worse or how long they survived:
Slovenian: V študijah raka kolona ali danke je bilo na splošno dokazano, da zdravilo Erbitux podaljša čas življenja bolnikov brez poslabšanja njihove bolezni ali čas njihovega preživetja:
English: In cancer that is recurrent (when it has come back after previous treatment) or metastatic, Erbitux is used with a ‘platinum-based' anticancer medicine combination (including medicines such as cisplatin or carboplatin).
Slovenian: Pri ponavljajočem (ki se ponovi po predhodnem zdravljenju) ali metastatskem raku se zdravilo Erbitux uporablja v kombinaciji z zdravili za zdravljenje raka na osnovi platine (vključno z zdravili, kot je cisplatin ali karboplatin).
English: What is the risk associated with Erbitux?
Slovenian: Kakšna tveganja so povezana z zdravilom Erbitux?
English: The active substance in Erbitux, cetuximab, is a monoclonal antibody.
Slovenian: Zdravilna učinkovina v zdravilu Erbitux, cetuksimab, je monoklonsko protitelo.
English: When RAS genes (such as KRAS) are mutated they can stimulate the tumour cells to grow without being switched on by EGFR, so Erbitux would not be expected to be of much help.
Slovenian: Kadar so geni RAS (kot je npr. gen KRAS) mutirani, lahko tumorske celice spodbudijo k rasti, ne da bi k njihovi aktivaciji pripomogel receptor za epidermalni rastni faktor, zato se ne pričakuje, da bi bilo zdravilo Erbitux koristno.
English: • two studies involved 1,535 patients who had not received chemotherapy before, looking at the effects of adding Erbitux to a treatment combination containing either irinotecan or oxaliplatin (FOLFOX); a third study looked also at the effects of adding Erbitux to two treatment combinations containing oxaliplatin (one of which was similar to FOLFOX) in 1,630 patients.
Slovenian: • v dve študiji je bilo vključenih 1 535 bolnikov, ki predhodno še niso bili zdravljeni s kemoterapijo, v njej pa so proučevali učinkovitost dodajanja zdravila Erbitux kemoterapevtskemu zdravljenju s kombinacijo zdravil, ki so vsebovala irinotekan ali oksaliplatin (FOLFOX); v tretji študiji so pri 1 630 bolnikih proučevali tudi učinke dodajanja zdravila Erbitux dvema zdravljenjema s kombinacijo zdravil, ki so vsebovale oksaliplatin (eno je bilo podobno zdravljenju FOLFOX);
English: • the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.
Slovenian: • v drugo študijo je bilo vključenih 442 bolnikov s ponavljajočim se ali metastatskim rakom, v njej pa so proučevali učinke dodajanja zdravila Erbitux kombinaciji zdravil proti raku na osnovi platine.
English: However, in the third study, patients with wild-type KRAS only survived overall for 16.3 months when Erbitux was added to the another oxaliplatin-based treatment similar to FOLFOX, compared with 18.2 months when the oxaliplatin-based treatment was used alone.
Slovenian: Vendar pa je bilo v tretji študiji celokupno preživetje bolnikov z divjim tipom gena KRAS le 16,3 meseca, kadar je bilo zdravilo Erbitux dodano zdravljenju z oksaliplatinom, podobnemu zdravljenju FOLFOX, v primerjavi s 18,2 meseca, če je bilo zdravljenje z oksaliplatinom uporabljeno samostojno;
English: When it is used on its own or with other anticancer medicines, Erbitux is continued for as long as the patient responds.
Slovenian: Kadar se zdravilo Erbitux uporablja samostojno ali skupaj z drugimi zdravili proti raku, se bolniku daje tako dolgo, dokler se nanj odziva.
English: Why has Erbitux been approved?
Slovenian: Zakaj je bilo zdravilo Erbitux odobreno?
English: In recurrent or metastatic head and neck cancer, survival was longer when Erbitux was added to a platinum-based anticancer medicine combination (10.1 months compared with 7.4 months, on average).
Slovenian: Pri ponavljajočem se ali metastatskem raku glave in vratu je bil čas preživetja daljši, kadar se je zdravilo Erbitux dodajalo kombinaciji zdravil proti raku na osnovi platine (povprečno 10,1 meseca v primerjavi s 7,4 meseca).
English: For metastatic cancer of the colon or rectum, Erbitux was studied in six main studies:
Slovenian: Pri metastatskem raku kolona ali danke so zdravilo Erbitux proučevali v šestih glavnih študijah:
English: Erbitux is also used to treat ‘squamous cell' cancers of the head and neck.
Slovenian: Zdravilo Erbitux se uporablja tudi za zdravljenje ploščatoceličnega raka glave in vratu.
English: Erbitux must not be used with oxaliplatin-containing chemotherapy for metastatic colorectal cancer in patients with mutated RAS or for whom RAS status is unknown.
Slovenian: Zdravilo Erbitux se ne sme uporabljati skupaj s kemoterapijo, ki vsebuje oksaliplatin, pri bolnikih z metastatskim rakom kolona ali danke z mutiranim genom RAS ali tistih, pri katerih stanje gena RAS ni znano.
English: Erbitux is used to treat metastatic cancer of the colon or rectum (large intestine).
Slovenian: Zdravilo Erbitux se uporablja za zdravljenje metastatskega raka kolona ali danke (debelega črevesa).
English: When it is used with radiotherapy, Erbitux is started one week before the radiotherapy starts and continued until the radiotherapy has finished.
Slovenian: Kadar se uporablja skupaj z obsevanjem, se začne zdravilo dajati en teden pred začetkom obsevanja in se daje vse do konca obsevanja.
English: Erbitux is a solution for infusion (drip into a vein) that contains the active substance cetuximab.
Slovenian: Zdravilo Erbitux je raztopina za infundiranje (kapalno infuzijo v veno), ki vsebuje zdravilno učinkovino cetuksimab.
English: • the first study in patients who had taken chemotherapy before did not look at RAS mutations, but in the other two studies, patients with wild-type KRAS in their tumours lived for longer without their disease getting worse when Erbitux was added to their treatment.
Slovenian: • v prvi študiji, izvedeni pri bolnikih, ki so predhodno že prejemali kemoterapijo, niso opazovali mutacij gena RAS, v drugih dveh študijah pa je pri bolnikih s tumorji z divjim tipom gena KRAS, ki so prejemali zdravilo Erbitux kot dodatek k zdravljenju, do poslabšanja bolezni prišlo pozneje.
English: Patients who had failed both oxaliplatin and irinotecan treatment lived for an average of 3.6 months without their disease getting worse with Erbitux, compared with 1.9 months in those receiving best supportive care alone (the treatment of symptoms but not the cancer itself).
Slovenian: Pri bolnikih, pri katerih zdravljenje z oksaliplatinom in irinotekanom ni bilo uspešno, se bolezen ni poslabšala povprečno 3,6 meseca pri bolnikih, ki so prejemali zdravilo Erbitux, v primerjavi z 1,9 meseca pri bolnikih, ki so prejemali samo podporno nego (zdravljenje simptomov, a ne samega raka).
English: In patients receiving Erbitux in combination with oxaliplatin-containing chemotherapy (FOLFOX) patients with wild-type RAS lived for longer without their disease getting worse compared with patients on FOLFOX alone (12.0 months compared with 5.8 months, on average).
Slovenian: Bolniki z divjim tipom gena RAS, ki so prejemali zdravilo Erbitux v kombinaciji s kemoterapijo, ki je vsebovala oksaliplatin (FOLFOX), so živeli dlje brez poslabšanja bolezni v primerjavi z bolniki, ki so prejemali samo zdravljenje FOLFOX (v povprečju 12,0 meseca v primerjavi s 5,8 meseca).
English: Most of the studies looked at the results separately in patients whose tumours had wildtype KRAS (one of the types of RAS genes) and patients whose tumours had mutated KRAS.
Slovenian: V večini študij so rezultate za bolnike s tumorji z divjim tipom gena KRAS (eno od vrste genov RAS) in za bolnike s tumorji z mutiranim genom KRAS analizirali ločeno.
English: In locally advanced head and neck cancers, the patients lived for longer without their disease getting worse when Erbitux was added to radiotherapy (24.4 months compared with 14.9 months, on average).
Slovenian: Pri lokalno napredovalem raku glave in vratu je bil čas do poslabšanja bolezni daljši pri bolnikih, ki so prejemali zdravilo Erbitux kot dodatek k obsevanju (povprečno 24,4 meseca v primerjavi s 14,9 meseca).
English: • in patients who had not received chemotherapy before, patients who had wild-type KRAS in their tumours lived for longer without their disease getting worse when they received Erbitux in addition to chemotherapy including irinotecan (9.9 months compared with 8.4 months, on average).
Slovenian: • pri bolnikih, ki predhodno niso bili zdravljeni s kemoterapijo, in bolnikih s tumorji z divjim tipom gena KRAS so tisti, ki so prejemali zdravilo Erbitux kot dodatek h kemoterapiji, vključno z irinotekanom, živeli dlje brez poslabšanja bolezni (v povprečju 9,9 meseca v primerjavi z 8,4 meseca).
English: Cetuximab has been designed to attach to EGFR, which can be found on the surface of some tumour cells.
Slovenian: Zdravilna učinkovina cetuksimab je bila zasnovana tako, da se veže na receptor za epidermalni rastni faktor, ki ga najdemo na površini nekaterih tumorskih celic.
English: What is Erbitux used for?
Slovenian: Za kaj se zdravilo Erbitux uporablja?
English: How has Erbitux been studied?
Slovenian: Kako je bilo zdravilo Erbitux raziskano?
English: • the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy;
Slovenian: • v prvo študijo, v kateri so proučevali učinke dodajanja zdravila Erbitux med obsevanjem, je bilo vključenih 424 bolnikov z lokalno napredovalnim rakom;
English: What is Erbitux?
Slovenian: Kaj je zdravilo Erbitux?
English: Patients who had failed oxaliplatin treatment lived for an average of 4.0 months without their disease getting worse with Erbitux plus irinotecan, compared with 2.6 months in those receiving irinotecan alone.
Slovenian: V skupini bolnikov, pri katerih zdravljenje z oksaliplatinom ni bilo uspešno, do poslabšanja ni prišlo povprečno 4,0 meseca pri bolnikih, ki so prejemali zdravilo Erbitux in irinotekan, in 2,6 meseca pri bolnikih, ki so prejemali samo irinotekan.